At the time of writing, Novo Nordisk ADR [NVO] stock is trading at $56.34, down -1.12%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NVO shares have gain 4.82% over the last week, with a monthly amount drifted -21.42%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Novo Nordisk ADR [NYSE: NVO] stock has seen the most recent analyst activity on August 13, 2025, when BNP Paribas Exane upgraded its rating to a Neutral but kept the price target unchanged to $54 for it. Previously, UBS downgraded its rating to Neutral on August 05, 2025. On July 31, 2025, downgrade downgraded it’s rating to Hold but maintained its price target of $57 on the stock. Barclays downgraded its rating to a Equal Weight. BMO Capital Markets downgraded its rating to a Market Perform but $64 remained the price target by the analyst firm on April 17, 2025. Kepler upgraded its rating to Buy for this stock on March 13, 2025. In a note dated March 03, 2025, Stifel downgraded an Hold rating on this stock.
For the past year, the stock price of Novo Nordisk ADR fluctuated between $45.05 and $139.74. Currently, Wall Street analysts expect the stock to reach $52.5 within the next 12 months. Novo Nordisk ADR [NYSE: NVO] shares were valued at $56.34 at the most recent close of the market. An investor can expect a potential drop of -6.82% based on the average NVO price forecast.
Analyzing the NVO fundamentals
According to Novo Nordisk ADR [NYSE:NVO], the company’s sales were 45.45B for trailing twelve months, which represents an 18.96% jump. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.46%, Pretax Profit Margin comes in at 0.45%, and Net Profit Margin reading is 0.36%. To continue investigating profitability, this company’s Return on Assets is posted at 0.23, Equity is 0.78 and Total Capital is 0.52. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.59.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 55.61 points at the first support level, and at 54.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 57.70, and for the 2nd resistance point, it is at 59.07.
Ratios To Look Out For
It is important to note that Novo Nordisk ADR [NYSE:NVO] has a current ratio of 0.78. In addition, the Quick Ratio stands at 0.56 and the Cash Ratio stands at 0.09. Considering the valuation of this stock, the price to sales ratio is 4.17, the price to book ratio is 9.46 and price to earnings (TTM) ratio is 15.52.
Transactions by insiders
Recent insider trading involved Novo Nordisk A/S, 10% Owner, that happened on May 30 ’25 when 0.92 million shares were purchased.
